Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00092274
Recruitment Status : Withdrawn (Acquired asset)
First Posted : September 27, 2004
Last Update Posted : April 21, 2015
Information provided by: